M

Mersana Therapeutics
D

MRSN

6.85000
USD
-0.29
(-4.06%)
مغلق
حجم التداول
3,299
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
34,186,240
أصول ذات صلة
AMGN
AMGN
3.67
(1.31%)
284.76 USD
C
CRSP
2.150
(4.08%)
54.870 USD
E
EDIT
0.24500
(9.74%)
2.76000 USD
INCY
INCY
1.220
(1.43%)
86.650 USD
N
NKTR
1.330
(3.70%)
37.270 USD
REGN
REGN
5.82
(1.03%)
572.98 USD
المزيد
الأخبار المقالات

العنوان: Mersana Therapeutics Inc

القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.